tiprankstipranks
Trending News
More News >
Hygeia Healthcare Holdings Co., Ltd. (HK:6078)
:6078
Hong Kong Market
Advertisement

Hygeia Healthcare Holdings Co., Ltd. (6078) AI Stock Analysis

Compare
1 Followers

Top Page

HK:6078

Hygeia Healthcare Holdings Co., Ltd.

(6078)

Rating:74Outperform
Price Target:
HK$19.00
▲(12.29%Upside)
Hygeia Healthcare's overall score is driven by strong financial performance and positive technical analysis indicators. The high market momentum and solid revenue growth are significant strengths, while the cash flow challenges and moderate valuation present areas for improvement.

Hygeia Healthcare Holdings Co., Ltd. (6078) vs. iShares MSCI Hong Kong ETF (EWH)

Hygeia Healthcare Holdings Co., Ltd. Business Overview & Revenue Model

Company DescriptionHygeia Healthcare Holdings Co., Limited operates as an oncology healthcare company in the People's Republic of China. The company owns and operates private for-profit hospitals that offer oncology healthcare services, such as tumor screening and genetic diagnosis, radiotherapy, surgery, chemotherapy, immunotherapy, targeted therapy, oncology rehabilitation, nutrition, and hospice care. It also provides radiotherapy center consulting services; and licenses its SRT equipment, as well as offers maintenance and technical support services for its SRT equipment. In addition, the company provides hospital and corporate management, and supply chain services. As of December 31, 2021, it operated or managed a network of 12 oncology-focused hospitals in 9 cities in 7 Provinces in the People's Republic of China. Hygeia Healthcare Holdings Co., Limited was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.
How the Company Makes MoneyHygeia Healthcare Holdings Co., Ltd. generates revenue primarily through the provision of medical services across its network of hospitals and clinics. The company's key revenue streams include inpatient and outpatient services, particularly those related to oncology treatments such as chemotherapy, radiotherapy, and surgery. Additionally, Hygeia Healthcare benefits from strategic partnerships with medical equipment suppliers and other healthcare providers, enhancing its service offerings and operational efficiency. The company's earnings are also supported by the growing demand for specialized cancer care in China, driven by an increasing incidence of cancer and a rising middle class with access to healthcare.

Hygeia Healthcare Holdings Co., Ltd. Financial Statement Overview

Summary
Hygeia Healthcare shows strong revenue growth and profitability with a solid balance sheet. However, the cash flow situation, particularly free cash flow generation, needs improvement to sustain long-term growth.
Income Statement
85
Very Positive
Hygeia Healthcare demonstrated strong revenue growth and profitability. The gross profit margin was robust at 29.36% for 2024, showing effective cost management. However, net profit margin decreased slightly to 13.45%, indicating some pressure on bottom-line profitability. Revenue grew by 9.06% from 2023 to 2024, showcasing continued expansion, but the slower growth compared to previous years may warrant monitoring.
Balance Sheet
78
Positive
The company's balance sheet reflects a healthy equity position, with a debt-to-equity ratio of 0.42 in 2024, indicating manageable leverage. Return on equity was solid at 8.99%, though slightly down from the previous year, suggesting efficient use of equity capital. The equity ratio is healthy at 60.88%, highlighting financial stability. However, increasing total debt levels could pose future risks.
Cash Flow
60
Neutral
Cash flow analysis reveals challenges with free cash flow generation, as free cash flow was null in 2024. The operating cash flow to net income ratio is unavailable, suggesting a need for better alignment of operating cash flows to net income. The company must focus on enhancing cash flow from operations to support ongoing investments and debt obligations.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue4.45B4.08B3.20B2.32B1.40B
Gross Profit1.31B1.29B1.02B744.66M471.96M
EBITDA999.10M1.11B868.43M623.67M385.36M
Net Income598.26M682.93M476.78M441.46M170.09M
Balance Sheet
Total Assets10.93B10.73B7.24B6.69B4.70B
Cash, Cash Equivalents and Short-Term Investments651.59M768.00M884.71M1.10B2.58B
Total Debt2.79B2.72B1.29B1.23B2.48M
Total Liabilities4.25B4.48B2.30B2.21B359.93M
Stockholders Equity6.65B6.23B4.93B4.46B4.27B
Cash Flow
Free Cash Flow92.02M-157.98M92.26M-236.84M-25.77M
Operating Cash Flow707.13M782.84M685.38M426.25M296.13M
Investing Cash Flow-671.09M-2.86B-372.06M-850.85M-2.48B
Financing Cash Flow-216.56M1.78B-154.21M754.50M2.17B

Hygeia Healthcare Holdings Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price16.92
Price Trends
50DMA
15.50
Positive
100DMA
14.96
Positive
200DMA
15.66
Positive
Market Momentum
MACD
0.32
Negative
RSI
65.66
Neutral
STOCH
76.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6078, the sentiment is Positive. The current price of 16.92 is above the 20-day moving average (MA) of 15.63, above the 50-day MA of 15.50, and above the 200-day MA of 15.66, indicating a bullish trend. The MACD of 0.32 indicates Negative momentum. The RSI at 65.66 is Neutral, neither overbought nor oversold. The STOCH value of 76.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6078.

Hygeia Healthcare Holdings Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
HK$6.71B26.4626.24%1.65%17.69%5.37%
74
Outperform
HK$10.39B16.419.30%7.28%-13.77%
70
Outperform
HK$8.76B27.1013.13%0.03%28.02%19.41%
69
Neutral
HK$9.00B28.652.78%1.81%-1.04%-20.43%
68
Neutral
HK$1.75B5.4324.13%4.09%-3.85%-19.28%
57
Neutral
HK$585.19M35.211.07%5.08%-1.20%-87.51%
52
Neutral
$7.63B0.11-62.96%2.08%16.16%0.31%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
16.92
-5.88
-25.79%
HK:1526
Rici Healthcare Holdings Ltd.
1.10
-0.11
-9.09%
HK:1951
Jinxin Fertility Group Ltd.
3.28
0.85
34.98%
HK:2273
Gushengtang Holdings Limited
37.10
3.88
11.68%
HK:2373
Beauty Farm Medical & Health Industry, Inc.
28.55
12.17
74.30%
HK:3689
Guangdong Kanghua Healthcare Co., Ltd. Class H
1.75
-0.79
-31.10%

Hygeia Healthcare Holdings Co., Ltd. Corporate Events

Hygeia Healthcare Announces AGM Results and Auditor Change
Jun 27, 2025

Hygeia Healthcare Holdings Co., Ltd. announced the results of its Annual General Meeting held on June 27, 2025, where all proposed resolutions were passed by shareholder vote. A significant change was the appointment of Deloitte Touche Tohmatsu as the new auditor, which may impact the company’s financial auditing processes and stakeholder confidence.

The most recent analyst rating on (HK:6078) stock is a Buy with a HK$37.00 price target. To see the full list of analyst forecasts on Hygeia Healthcare Holdings Co., Ltd. stock, see the HK:6078 Stock Forecast page.

Hygeia Healthcare Announces 2025 Annual General Meeting
Jun 3, 2025

Hygeia Healthcare Holdings Co., Ltd. has announced its upcoming Annual General Meeting scheduled for June 27, 2025, in Hong Kong. The meeting will address several key resolutions, including the adoption of financial statements, re-election of directors, appointment of auditors, and authorization for the board to manage share allotments. These resolutions are crucial for the company’s governance and strategic direction, potentially impacting its operational and financial management.

The most recent analyst rating on (HK:6078) stock is a Buy with a HK$37.00 price target. To see the full list of analyst forecasts on Hygeia Healthcare Holdings Co., Ltd. stock, see the HK:6078 Stock Forecast page.

Hygeia Healthcare Enters New Procurement Agreement with Handan Renhe Hospital
May 29, 2025

Hygeia Healthcare Holdings Co., Ltd. has entered into a new 2025 Procurement Framework Agreement with Handan Renhe Hospital, replacing the existing procurement agreements. This agreement allows Gamma Star Tech, a subsidiary of Hygeia, to supply medicine and medical consumables to Handan Renhe Hospital, enhancing operational efficiency and continuing their business relationship. The transactions are classified as continuing connected transactions under Hong Kong’s Listing Rules, requiring reporting and annual review but exempt from independent shareholders’ approval due to the percentage ratios involved.

The most recent analyst rating on (HK:6078) stock is a Buy with a HK$37.00 price target. To see the full list of analyst forecasts on Hygeia Healthcare Holdings Co., Ltd. stock, see the HK:6078 Stock Forecast page.

Hygeia Healthcare Announces Board and Operational Changes
May 29, 2025

Hygeia Healthcare Holdings Co., Ltd. has announced several changes in its board and operations, including the retirement of Mr. Liu Yanqun from his roles as an independent non-executive director and various committee positions, effective May 29, 2025. Mr. Zhang Guozhong, with over 25 years of experience in healthcare management, has been appointed as the new independent non-executive director. Additionally, the company is proposing a change of auditor and has updated its principal place of business in Hong Kong. These changes are expected to enhance the company’s governance and operational efficiency.

The most recent analyst rating on (HK:6078) stock is a Buy with a HK$37.00 price target. To see the full list of analyst forecasts on Hygeia Healthcare Holdings Co., Ltd. stock, see the HK:6078 Stock Forecast page.

Hygeia Healthcare Announces Board Composition and Roles
May 29, 2025

Hygeia Healthcare Holdings Co., Ltd. has announced the composition of its board of directors and their respective roles within the company. This announcement details the executive and independent non-executive directors, as well as their participation in various board committees, which is crucial for stakeholders to understand the governance structure and leadership dynamics of the company.

The most recent analyst rating on (HK:6078) stock is a Buy with a HK$37.00 price target. To see the full list of analyst forecasts on Hygeia Healthcare Holdings Co., Ltd. stock, see the HK:6078 Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 25, 2025